Keywords: OSI Pharmaceuticals, Genentech, Roche, Tarceva, NSCLC, Maintenance therapy
OSI/Genentech gain additional indication from US FDA for Tarceva as maintenance therapy for advanced NSCLC
Article | 19 April 2010
USA-based OSI Pharmaceuticals, which is fending off a hostile $3.5 billion takeover bid from Japan's Astellas, received welcome news last Friday, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
